Alzheimer Disease Clinical Trial
Official title:
Effects of 24-week Computerized Cognitive Training on Microbiota-gut-brain Axis in Patients With Mild Cognitive Impairment and Mild Alzheimer's Disease: a Randomized Controlled Trial
Verified date | October 2023 |
Source | Chongqing Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aims to testify multi-domain effects of computerized cognitive training in patients with mild cognitive impairment and mild Alzheimer's disease through multi-dimensional evaluation.
Status | Completed |
Enrollment | 84 |
Est. completion date | August 19, 2022 |
Est. primary completion date | August 19, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 55 Years to 90 Years |
Eligibility | Inclusion Criteria: - between 55 and 90 years of age; - a Clinical Dementia Rating (CDR) score of 0.5 or 1; - at least three months of stable doses if receiving antidementia medication or mood-stabilizing medication for mild AD participants; - primary school education and above; - accompanied by a consistent caregiver (at least 5 days/week); - informed consent. Exclusion Criteria: - factors that might preclude completion of assessments; - severe psychiatric illness and the use of antidepressants; - any condition that would preclude completion of training and follow-up tests; - other disorders that would affect cognition. |
Country | Name | City | State |
---|---|---|---|
China | The First Affiliated Hospital of Chongqing Medical University | Chongqing | Chongqing |
Lead Sponsor | Collaborator |
---|---|
Chongqing Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Global Cognition | The Alzheimer's Disease Assessment Scale- cognitive subscale (11 items) will be used to evaluate global cognition and served as the primary outcome measure. The minimum and maximum values are 0 and 70 respectively, and higher scores mean a worse outcome. | baseline, 4, 12, 24 weeks | |
Secondary | Learning | The Auditory Verbal Learning Test (minimum to maximum: 0-45) will be applied, and higher scores mean a better outcome for the scale. | baseline, 4, 12, 24 weeks | |
Secondary | Episodic Memory | The Free and Cued Selective Reminding Test (minimum to maximum: 0-48) will be applied, and higher scores mean a better outcome for the scale. | baseline, 4, 12, 24 weeks | |
Secondary | Attention | The Trail Making Test (minimum to maximum: 0-24) will be applied, and higher scores mean a better outcome for the scale. | baseline, 4, 12, 24 weeks | |
Secondary | Executive Function | The Digital Span Test (minimum to maximum: 0-10) will also be applied, and higher scores mean a better outcome for the scale. | baseline, 4, 12, 24 weeks | |
Secondary | Visuospatial Function | The Clock Drawing Test (minimum to maximum: 0-15) will be applied, and higher scores mean a better outcome for the scale. | baseline, 4, 12, 24 weeks | |
Secondary | Verbal Ability | The Boston Naming Test (minimum to maximum: 0-30) will be applied, and higher scores mean a better outcome for the scale. | baseline, 4, 12, 24 weeks | |
Secondary | Verbal Frequency | The Verbal Frequency Test (minimum: 0, no maximum) will also be applied, and higher scores mean a better outcome for the scale. | baseline, 4, 12, 24 weeks | |
Secondary | Neuropsychiatric Symptoms | The Neuropsychiatric Inventory (minimum to maximum: 0-144) will be used, and higher scores mean a worse outcome for the scale. | baseline, 4, 12, 24 weeks | |
Secondary | Depression | The 30-Geriatric Depression Scale (minimum to maximum: 0-30) will be used, and higher scores mean a worse outcome for the scale. | baseline, 4, 12, 24 weeks | |
Secondary | Daily Living Function | The Instrumental Activities of Daily Living scale (minimum to maximum: 0-31) will be used, and higher scores mean a worse outcome for this scale. | baseline, 4, 12, 24 weeks | |
Secondary | Severity of Cognitive Impairment | The Clinical Dementia Rating scale (sum of boxes, minimum to maximum: 0-18) will be used, and higher scores mean a worse outcome for this scale. | baseline, 4, 12, 24 weeks | |
Secondary | Brain Functional Connectivity | The regions of interests (ROIs) are selected as the Brodmann Area (BA) 9 and 46 (overlapping the dorsolateral prefrontal cortex, DLPFC), left Brodmann Area 6 (overlapping pre-Motor and Supplementary Motor Cortex, PM-SMC), and right Brodmann Area 45 (overlapping pars triangularis Broca's area). For each resting-state dataset of fNIRS, functional connectivity (FC) will be analyzed by Spearman's correlation between the time series of each ROI-to-ROI pair. | baseline and 24 weeks | |
Secondary | Alpha-diversity of Gut Microbiome | Fecal samples will be collected from patients in standard 300 mL sterilin tubes and frozen immediately at -80°C. Patients will be asked to produce the first-morning sample for consistency and to avoid alcohol the previous 24 h. After 16S rRNA high-throughput sequencing, the diversity analysis of species under a sample (a-diversity) of the bacteria on Genus, will be analyzed in R. | baseline and 24 weeks | |
Secondary | Beta-diversity of Gut Microbiome | After 16S rRNA high-throughput sequencing, the cluster analysis between different samples (ß-diversity) will be analyzed in R. | baseline and 24 weeks | |
Secondary | Composition of Gut Microbiome | After 16S rRNA high-throughput sequencing, the compositional analysis of bacteria on genus will be analyzed in R. | baseline and 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |